PULMONARY HYPERTENSION Featured Archive
Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.
Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.
The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.
Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus in pulmonary arterial hypertension should be considered separate diseases.
Lung transplantation may be an option in patients with severe pulmonary arterial hypertension who do not respond well to medical therapy.
Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.
Pulmonary and thoracic symptoms often coincide with initial presentation of connective tissue disease.
Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.
Respiratory muscle dysfunction, iron deficiency, and skeletal muscle dysfunction have been implicated as mechanisms for exercise intolerance in pulmonary arterial hypertension.
Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.
Pulmonary arterial hypertension tends to vary in presentation in patients of different races and ethnicities.
Prenatal factors such as intrauterine growth retardation, infection, and placental inflammation can affect lung development in neonates.
Meta-analysis supports anti-RNP and anti-Sm antibodies as serological biomarkers of PAH risk in patients with SLE.
Pulmonary and genetics experts James E. Loyd, MD, and Wendy Chung, MD, PhD, offer insight into the role of genetics in pulmonary arterial hypertension.